(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 September 2009 (24.09.2009)

PCT

(10) International Publication Number
WO 2009/115547 A8

(51) International Patent Classification:
C07D 249/14 (2006.01) *A61K 31/4196* (2006.01)
C07D 401/04 (2006.01) *A61K 31/4439* (2006.01)
C07D 401/14 (2006.01) *A61P 25/00* (2006.01)
C07D 405/04 (2006.01)

(21) International Application Number:
PCT/EP2009/053186

(22) International Filing Date:
18 March 2009 (18.03.2009)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
08152987.7 19 March 2008 (19.03.2008) EP

(71) Applicant *(for all designated States except US)*: **JANSSEN PHARMACEUTICA NV** [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MACDONALD, Gregor, James** [GB/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **THURING, Johannes, Wilhelmus, John F.** [NL/BE]; Belegstraat 26, B-2018 Antwerpen (BE). **STANISLAWSKI, Pauline, Carol** [AU/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **ZHUANG, Wei** [CN/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **VAN ROOSBROECK, Yves, Emiel, Maria** [BE/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE). **VAN DEN KEYBUS, Frans, Alfons, Maria** [BE/BE]; c/o Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340 Beerse (BE).

(74) Common Representative: **JANSSEN PHARMACEUTICA NV**; Turnhoutseweg 30, B-2340 Beerse (BE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

[Continued on next page]

(54) Title: TRISUBSTITUTED 1, 2, 4 -TRIAZOLES AS NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS



(I)

(57) Abstract: The present invention relates to 1-aryl-3-aniline-5-alkyl-1, 2,4-triazole derivatives and analogues or pharmaceutically acceptable salts thereof, processes for preparing them, pharmaceutical compositions containing them and their use in therapy, according to Formula (I). The invention particularly relates to potent positive allosteric modulators of nicotinic acetylcholine receptors, such positive allosteric modulator having the capability to increase the efficacy of nicotinic receptor agonists.

WO 2009/115547 A8

WO 2009/115547 A8

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
26 November 2009

(15) Information about Correction:
see Notice of 26 November 2009